AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04975308
Drug: Imlunestrant
RxNorm normalized name: Imlunestrant
DrugBank: Imlunestrant (DB19043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04975308
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04975308
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered IM.
Trial: NCT04975308
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally.
Trial: NCT05740813
Drug: ABBV-CLS-7262 Dose 1
RxNorm normalized name: Calf lung surfactant extract (CLSE)
DrugBank: ABBV-CLS-7262 (DB18407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-CLS-7262 is administered orally once per day for 24 weeks.
Trial: NCT05740813
Drug: ABBV-CLS-7262 Dose 2
RxNorm normalized name: Calf lung surfactant extract (CLSE)
DrugBank: ABBV-CLS-7262 (DB18407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-CLS-7262 is administered orally once per day for 24 weeks.
Trial: NCT05348876
Drug: Darolutamide (Nubeqa, BAY1841788)
RxNorm normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 600 mg (two 300 mg) tablets of darolutamide to be taken orally twice a day at about 12-hour intervals, equivalent to a total daily dose of 1200 mg.
Trial: NCT06136988
Drug: Docetaxel for Injection (Albumin-bound)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel for Injection (Albumin-bound) 60 or 75 mg/m\^2, Intravenous infusion, Q3W
Trial: NCT06136988
Drug: SG001
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 360 mg, Intravenous infusion, Q3W
Trial: NCT06136988
Drug: Cisplatin for injection
RxNorm normalized name: Cisplatin for Injection
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin for injection, 25 mg/m\^2, Intravenous infusion, D1-D3, Q3W
Trial: NCT06136988
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 135 mg/m\^2, Intravenous infusion, Q3W
Trial: NCT05836779
Drug: CBL-514 injection
RxNorm normalized name: OH-Cbl
DrugBank: Hydroxocobalamin (DB00200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CBL-514 will be administered at the raised area of cellulite.
Trial: NCT05829187
Drug: Dihydroartemisinin
RxNorm normalized name: Dihydroartemisinin
DrugBank: Artenimol (DB11638)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: dihidroartemisinin dose of 2-4 mg/Kg Body weight taken for 3 days
Trial: NCT05829187
Drug: Piperaquine
RxNorm normalized name: Piperaquine
DrugBank: Piperaquine (DB13941)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: piperaquine at a dose of 16-32 mg/Kg body weight taken for 3 days
Trial: NCT05829187
Drug: Primaquine
RxNorm normalized name: Primaquine
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Primaquine dose 0.25 mg/kg body weight given to uncomplicated Plasmodium falciparum patients on the first day only
Trial: NCT05132582
Drug: Tucatinib
RxNorm normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300mg given by mouth (orally) twice daily
Trial: NCT05132582
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 6mg/kg given into the vein (IV; intravenously) or 600mg injected under the skin (SC; subcutaneous) every 21 days
Trial: NCT05132582
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 420mg given by IV every 21 days
Trial: NCT05132582
Drug: Combination product: Trastuzumab + Pertuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase will be given by subcutaneous injection every 21 days. May be given in place of trastuzumab and pertuzumab individually.
Trial: NCT05074810
Drug: avutometinib and sotorasib
RxNorm normalized name: sotorasib
DrugBank: Avutometinib (DB15254)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The RP2D of avutometinib + sotorasib determined in Part A will be used in Part B dose expansion
Trial: NCT05074810
Drug: avutometinib and sotorasib and defactinib
RxNorm normalized name: sotorasib
DrugBank: Defactinib (DB12282)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The RP2D of avutometinib + sotorasib + defactinib determined in Part A will be used in Part B dose expansion
Trial: NCT05198310
Drug: KPL-404
RxNorm normalized name: Immunoglobulin G4 [222-proline], anti-(human CD40 antigen) (human-Mus musculus monoclonal KPL-404 γ4-chain), disulfide with human-Mus musculus monoclonal KPL-404 κ-chain, dimer
DrugBank: Abiprubart (DB19333)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humanized monoclonal antibody
Trial: NCT05388149
Drug: Neratinib
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neratinib administered as 40mg tablets
Trial: NCT06103838
Drug: 18F-fluciclovine injection
RxNorm normalized name: fluciclovine (18F)
DrugBank: Fluciclovine (18F) (DB13146)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 370 MBq (10 mCi)(+/-20%) as a bolus intravenous injection.
Trial: NCT05543278
Drug: Amiodarone
RxNorm normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomized to the Amiodarone Arm will receive a 5-day course of amiodarone after surgery.
Trial: NCT06524830
Drug: VLS-01-203 BU
RxNorm normalized name: VL-2397
DrugBank: VL-2397 (DB17796)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VLS-01 buccal transmucosal administration
Trial: NCT04957095
Drug: Apomorphine Injectable Solution
RxNorm normalized name: apomorphine Injectable Solution
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apomorphine injected for therapeutic relief
Trial: NCT05832827
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib will be administered at a dose of 8 mg orally QD every 21 days (3 weeks) for up to 4 cycles in the induction phase, followed by 20 mg QD for up to 31 cycles in the maintenance phase. Then, further maintenance therapy with lenvatinib will be allowed until progression or unacceptable adverse events.
Trial: NCT05832827
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin will be administered at a dose of AUC 5 intravenously every 21 days (3 weeks) for up to 4 cycles in the induction phase.
Trial: NCT05832827
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel will be administered at a dose of 175 mg/m\^2 intravenously every 21 days (3 weeks) for up to 4 cycles in the induction phase.
Trial: NCT06224530
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose of 500mg levetiracetam The capsules of levetiracetam and placebo will be visibly the same.
Trial: NCT06213857
Drug: Mesalamine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A 5-aminosalicylic acid compound used in the treatment of mild to moderate ulcerative colitis, with high rates of efficacy in induction and maintenance of remission.
Trial: NCT05755386
Drug: iptacopan
RxNorm normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
Trial: NCT05250947
Drug: Platelet Rich Plasma
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 ml will be injected in up to 4 facet joints (2 levels) at 1.5 ml per joint
Trial: NCT06068686
Drug: Vildagliptin 50 MG
RxNorm normalized name: vildagliptin 50 MG
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: vildagliptin plus their metformin.
Trial: NCT06068686
Drug: Glimepiride 3 Mg Oral Tablet
RxNorm normalized name: glimepiride 3 MG Oral Tablet
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: glimepiride plus their metformin
Trial: NCT05774873
Drug: IBI334 D
RxNorm normalized name: D
DrugBank: Rosomidnar (DB17154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive IBI334 D once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
Trial: NCT05774873
Drug: IBI334 C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive IBI334 C once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
Trial: NCT05774873
Drug: IBI334 E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive IBI334 C once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
Trial: NCT05084534
Drug: Midodrine
RxNorm normalized name: Midodrine
DrugBank: Midodrine (DB00211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Midodrine starting at 0.25mg/kg/day in divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10% (maximum dose - 15mg/day)~• Midodrine dosage will be decreased by 25% in case of arterial hypertension (\>95th centile BP for the age)
Trial: NCT06280703
Drug: Insulin Degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered Intravenously (IV)
Trial: NCT06280703
Drug: Insulin Lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered Intravenously (IV)
Trial: NCT06280703
Drug: insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SC
Trial: NCT06271616
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT06086431
Drug: 0.9% sodium chloride
RxNorm normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the erector spine plane block
Trial: NCT06086431
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the erector spine plane block
Trial: NCT06086431
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.1ug/kg Dexmedetomidine for the erector spine plane block
Trial: NCT04768764
Drug: Bupivacain
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 ml %0,5 Bupivacaine will be diluted with 10 ml saline solution. Bupivacaine 0.25% Injectable Solution
Trial: NCT05597085
Drug: Inotuzumab Ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inotuzumab Ozogamicin is an Antibody drug conjugate directed against CD 22 positive B Cell ALL
Trial: NCT04877288
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04877288
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04877288
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT04625283
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in the ketamine arm will receive intraoperative and postoperative ketamine.
Trial: NCT05990998
Drug: 68Ga-DOTATATE and 68Ga-FAPI
RxNorm normalized name: 68Ga-DOTATATE
DrugBank: Dotatate (DB14554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient receive a single intravenous injection of 68Ga-FAPI or 68Ga-DOTATATE (2-4mCi) , and undergo PET/CT scan at 40-60 min post injection.
Trial: NCT06162728
Drug: Briquilimab
RxNorm normalized name: Briquilimab
DrugBank: Briquilimab (DB18136)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Administration
Trial: NCT04823585
Drug: Mepolizumab
RxNorm normalized name: Mepolizumab
DrugBank: Mepolizumab (DB06612)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution. Subcutaneous. Mepolizumab is a biological drug, a humanized monoclonal antibody against interleukin-5.
Trial: NCT05259709
Drug: cemiplimab
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered by IV infusion every 3 weeks (Q3W).
Trial: NCT04644289
Drug: olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib tablets are administrated orally 300 mg twice daily.
Trial: NCT04644289
Drug: durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab is administered 1500mg iv as a single dose prior to surgery (corresponding to 1 single cycle) .
Trial: NCT06066515
Drug: survodutide
RxNorm normalized name: Survodutide
DrugBank: Survodutide (DB18989)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once weekly subcutaneous injection
Trial: NCT05245396
Drug: Evobrutinib MR-T1
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of MR-T1 on Day 1 in treatment period 1, 2, and 3 of Part A.
Trial: NCT05245396
Drug: Evobrutinib MR-T2
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of MR-T2 on Day 1 in treatment period 1, 2, and 3 of Part A.
Trial: NCT05245396
Drug: Evobrutinib MR-T3
RxNorm normalized name: T3
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of MR-T3 on Day 1 in treatment period 1, 2, and 3 of Part A.
Trial: NCT06108050
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-PD1 antibody
Trial: NCT06184750
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05245396
Drug: Evobrutinib MR-T4
RxNorm normalized name: T4
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of MR-T4 on Day 1 in treatment period 1, 2, and 3 of Part A.
Trial: NCT06639607
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT05245396
Drug: Evobrutinib MUPS-C1
RxNorm normalized name: C1-INH
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of MUPS-C1 on Day 1 in treatment period 1, 2, and 3 of Part B.
Trial: NCT00528255
Drug: Misoprostol Vaginal Insert (MVI 100)
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The MVI 100 is misoprostol 100 mcg, formulated in a sustained release, nonbiodegradeable hydrogel polymer, with a polyester knit retrieval tape; IV oxytocin is permitted ad lib 30 minutes following removal of the MVI assuming no contraindications.
Trial: NCT05836987
Drug: Continuous DOAC therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DOACs will be prescribed to patients according to the treating healthcare provider(s) according to labeling instructions.
Trial: NCT06169397
Drug: XTMAB-16
RxNorm normalized name: XTMAB-16
DrugBank: XTMAB-16 (DB18380)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XTMAB-16 infusion
Trial: NCT05245396
Drug: Evobrutinib MUPS-C2
RxNorm normalized name: Evobrutinib
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of MUPS-C2 on Day 1 in treatment period 1, 2, and 3 of Part B.
Trial: NCT05245396
Drug: Evobrutinib MUPS-C3
RxNorm normalized name: Evobrutinib
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of MUPS-C3 on Day 1 in treatment period 1, 2, and 3 of Part C.
Trial: NCT05245396
Drug: Evobrutinib MUPS-C4
RxNorm normalized name: Evobrutinib
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of MUPS-C4 on Day 1 in treatment period 1, 2, and 3 of Part C.
Trial: NCT05245396
Drug: Evobrutinib MR-T adapated
RxNorm normalized name: Evobrutinib
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of MR-T adapted on Day 1 in treatment period 1, 2, and 3 of Part D.
Trial: NCT04696185
Drug: Dapagliflozin 10 MG
RxNorm normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin 10 mg (daily oral dose)
Trial: NCT05178043
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab 240mg to be administered as an intravenous (IV) infusion every 2 weeks (Q2W).
Trial: NCT04298541
Drug: Ga-68- DOTATATE
RxNorm normalized name: Gallium (Ga 68) dotatate
DrugBank: Dotatate (DB14554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study intervention consists of two PET scans that will be performed using two different radiotracers, 68-Ga-DOTATATE and 68-Ga-DOTATOC. Ga-68-DOTATATE and 68-Ga-DOTATOC are PET radiotracers targeting somatostatin receptors.~The study intervention consists of 2 PET scans that will be performed at least 24h apart using 68-Ga-DOTATATE and 68-Ga-DOTATOC radiotracers, in patients with suspected meningioma that are planned for subsequent surgery.
Trial: NCT04298541
Drug: Ga-68-DOTATOC
RxNorm normalized name: EDOTREOTIDE GALLIUM GA-68 4 mCi in 1 mL INTRAVENOUS INJECTION, SOLUTION [Ga-68-DOTATOC]
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study intervention consists of two PET scans that will be performed using two different radiotracers, 68-Ga-DOTATATE and 68-Ga-DOTATOC. Ga-68-DOTATATE and 68-Ga-DOTATOC are PET radiotracers targeting somatostatin receptors.~The study intervention consists of 2 PET scans that will be performed at least 24h apart using 68-Ga-DOTATATE and 68-Ga-DOTATOC radiotracers, in patients with suspected meningioma that are planned for subsequent surgery.
Trial: NCT04757740
Drug: methylprednisolone acetate and lidocaine
RxNorm normalized name: lidocaine hydrochloride / methylprednisolone acetate Injectable Suspension
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intra-articular injection of Mixture of 40 mg of methylprednisolone acetate(1 ml) and 1% lidocaine (2.5 ml). intra-articular steroid
Trial: NCT04422795
Drug: Ethyl chloride skin refrigerant spray
RxNorm normalized name: ethyl chloride Topical Spray
DrugBank: Ethyl chloride (DB13259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethyl chloride skin refrigerant spray is applied to the area of injection for 3 seconds immediately before needle insertion
Trial: NCT04682691
Drug: metoclopramide (10mg)
RxNorm normalized name: metoclopramide 10 MG
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral metoclopramide (10mg)
Trial: NCT06497036
Drug: Nplate
RxNorm normalized name: Nplate
DrugBank: Romiplostim (DB05332)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subcutaneous injection
Trial: NCT06410040
Drug: Lorlatinib
RxNorm normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lolatinib 100mg qd po
Trial: NCT04883957
Drug: BGB-11417
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablets administered orally as specified in the treatment arm.
Trial: NCT04624841
Drug: Indocyanine Green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2.5-7.5 mg (0.05 mg/kg) injection